Erin E Hahn1,2, Ron D Hays1,3,4, Katherine L Kahn3,4, Mark S Litwin1,5, Patricia A Ganz1,6. 1. UCLA Fielding School of Public Health, University of California, Los Angeles, CA, USA. 2. Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA. 3. Department of Medicine, Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine, University of California, Los Angeles, CA, USA. 4. RAND Corporation, Santa Monica, CA, USA. 5. Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA. 6. Division of Cancer Prevention and Control Research Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USA.
Abstract
PURPOSE: The purpose of this study was to determine the prevalence of post-traumatic stress symptoms in a sample of cancer survivors and to investigate their association with the impact of cancer, depressive symptoms, and social support. METHODS: We administered a survey to participants in a cancer survivor registry. It included: Post-Traumatic Stress Disorder Checklist-Civilian version (PCL-C), Impact of Cancer Scale (IOC) v.2, and measures of social support, income, and long-term effects of cancer. We performed multivariate analyses to estimate associations between PCL-C and other variables. PCL-C score was examined as a continuous dependent variable and categorically. RESULTS: Responses were available from 162 cancer survivors. Mean age was 51 years (standard deviation (SD) 16); mean time since diagnosis was 11 years (SD 10). Mean PCL-C score was 27 (SD 9, range 17-64); 29% of the sample scored 30 and above, 13% scored 38 and above, 7% scored 44 and above. Linear regression indicated that PCL-C scores were significantly associated with the IOC negative impact summary scale (NIS) (p < 0.001), depressive symptoms (p = 0.003), less social support (p = 0.02), and lower income (p = 0.03). NIS subscale analyses showed that two subscales, life interference (LI) and worry (W), were significantly correlated with PCL-C score (LI: p < 0.001; W: p = 0.02). CONCLUSIONS: In this study, the IOC NIS was associated with endorsement of PTSD symptoms. Assessing survivors for PTSD symptoms with the PCL-C could detect those individuals in need of psychosocial support. The IOC may be useful for identifying target areas for interventions to reduce these symptoms among cancer survivors.
PURPOSE: The purpose of this study was to determine the prevalence of post-traumatic stress symptoms in a sample of cancer survivors and to investigate their association with the impact of cancer, depressive symptoms, and social support. METHODS: We administered a survey to participants in a cancer survivor registry. It included: Post-Traumatic Stress Disorder Checklist-Civilian version (PCL-C), Impact of Cancer Scale (IOC) v.2, and measures of social support, income, and long-term effects of cancer. We performed multivariate analyses to estimate associations between PCL-C and other variables. PCL-C score was examined as a continuous dependent variable and categorically. RESULTS: Responses were available from 162 cancer survivors. Mean age was 51 years (standard deviation (SD) 16); mean time since diagnosis was 11 years (SD 10). Mean PCL-C score was 27 (SD 9, range 17-64); 29% of the sample scored 30 and above, 13% scored 38 and above, 7% scored 44 and above. Linear regression indicated that PCL-C scores were significantly associated with the IOC negative impact summary scale (NIS) (p < 0.001), depressive symptoms (p = 0.003), less social support (p = 0.02), and lower income (p = 0.03). NIS subscale analyses showed that two subscales, life interference (LI) and worry (W), were significantly correlated with PCL-C score (LI: p < 0.001; W: p = 0.02). CONCLUSIONS: In this study, the IOC NIS was associated with endorsement of PTSD symptoms. Assessing survivors for PTSD symptoms with the PCL-C could detect those individuals in need of psychosocial support. The IOC may be useful for identifying target areas for interventions to reduce these symptoms among cancer survivors.
Authors: Neomi Vin-Raviv; Grace Clarke Hillyer; Dawn L Hershman; Sandro Galea; Nicole Leoce; Dana H Bovbjerg; Lawrence H Kushi; Candyce Kroenke; Lois Lamerato; Christine B Ambrosone; Heidis Valdimorsdottir; Lina Jandorf; Jeanne S Mandelblatt; Wei-Yann Tsai; Alfred I Neugut Journal: J Natl Cancer Inst Date: 2013-02-21 Impact factor: 13.506
Authors: Ioannis Anastasiou; Konstantina G Yiannopoulou; Anastasios Mihalakis; Nikolaos Hatziandonakis; Constantinos Constantinides; Charalambos Papageorgiou; Dionisios Mitropoulos Journal: Am J Mens Health Date: 2010-05-18
Authors: Shah-Jalal Sarker; Sophia K Smith; Kashfia Chowdhury; Patricia A Ganz; Sheryl Zimmerman; John Gribben; Ania Korszun Journal: Support Care Cancer Date: 2016-11-08 Impact factor: 3.603
Authors: Lauren C Brown; Amy R Murphy; Chloe S Lalonde; Preeti D Subhedar; Andrew H Miller; Jennifer S Stevens Journal: Cancer Date: 2020-05-06 Impact factor: 6.921